Article Text

Download PDFPDF
Brivaracetam and levetiracetam dose adjustments leading to behavioural adverse effects
  1. May Yung Tiet,
  2. Jithin George
  1. Department of Neurology, Leicester General Hospital, Leicester, UK
  1. Correspondence to Dr May Yung Tiet, Department of Neurology, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK; m.tiet{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

With the recent approval of brivaracetam, the high-affinity synaptic vesicle protein 2A (SV2A) ligand, it has previously been suggested that patients on levetiracetam may benefit from switching to brivaracetam.1 The behavioural issues related to its predecessor, levetiracetam, are well known. Treatment with levetiracetam was associated with a seven-fold increase in the risk of depression.2 Nonetheless, rapid loading, easy conversion from oral to intravenous preparations, efficacy for focal and generalised seizures,3 and despite lack of supportive evidence, its use as a preferred third-line …

View Full Text


  • Contributors MYT wrote the manuscript. JG edited the manuscript.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.